Search

Your search keyword '"Fujii, N."' showing total 11 results
Start Over Author "Fujii, N." Journal bone marrow transplantation
11 results on '"Fujii, N."'

6. Erratum: Pre-transplant risk factors for cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia after hematopoietic cell transplantation

Author

Nakasone, H, primary, Onizuka, M, additional, Suzuki, N, additional, Fujii, N, additional, Taniguchi, S, additional, Kakihana, K, additional, Ogawa, H, additional, Miyamura, K, additional, Eto, T, additional, Sakamaki, H, additional, Yabe, H, additional, Morishima, Y, additional, Kato, K, additional, Suzuki, R, additional, and Fukuda, T, additional

Published
2013
Full Text
View/download PDF

7. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT

Author

Yoshihara, S, primary, Maruya, E, additional, Taniguchi, K, additional, Kaida, K, additional, Kato, R, additional, Inoue, T, additional, Fujioka, T, additional, Tamaki, H, additional, Ikegame, K, additional, Okada, M, additional, Soma, T, additional, Hayashi, K, additional, Fujii, N, additional, Onuma, T, additional, Kusunoki, Y, additional, Saji, H, additional, and Ogawa, H, additional

Published
2011
Full Text
View/download PDF

9. Allogeneic peripheral blood stem cell transplantation for the treatment of chronic active Epstein–Barr virus infection

Author

Fujii, N, primary, Takenaka, K, additional, Hiraki, A, additional, Maeda, Y, additional, Ikeda, K, additional, Shinagawa, K, additional, Ashiba, A, additional, Munemasa, M, additional, Sunami, K, additional, Hiramatsu, Y, additional, Ishimaru, F, additional, Niiya, K, additional, Yoshino, T, additional, and Harada, M, additional

Published
2000
Full Text
View/download PDF

10. Post-transplantation cyclophosphamide restores early B-cell lymphogenesis that suppresses subsequent chronic graft-versus-host disease.

Author

Iwamoto M, Ikegawa S, Kondo T, Meguri Y, Nakamura M, Sando Y, Sugiura H, Sumii Y, Asada N, Ennishi D, Nishimori H, Fujii K, Fujii N, Shibakura M, Maeda Y, and Matsuoka KI

Subjects
B-Lymphocytes, Cyclophosphamide, Humans, Transplantation Conditioning, Graft vs Host Disease drug therapy, Hematopoietic Stem Cell Transplantation
Published
2021
Full Text
View/download PDF

11. Prospective evaluation of alternative donor from unrelated donor and cord blood in adult acute leukemia and myelodysplastic syndrome.

Author

Terakura S, Nishida T, Sawa M, Kato T, Miyao K, Ozawa Y, Goto T, Kohno A, Ozeki K, Onishi Y, Fukuhara N, Fujii N, Yokoyama H, Kasai M, Iida H, Kanemura N, Endo T, Ago H, Onizuka M, Iyama S, Nawa Y, Nakamae M, Nagata Y, Kurahashi S, Tomiya Y, Yanagisawa A, Suzuki R, Kuwatsuka Y, Atsuta Y, Miyamura K, and Murata M

Subjects
Adult, Fetal Blood, Humans, Prospective Studies, Retrospective Studies, Unrelated Donors, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute therapy, Myelodysplastic Syndromes therapy
Abstract

A prospectively registered observational study was conducted to assess the significance of allogeneic hematopoietic stem cell transplantation from highly HLA-matched unrelated donors (UD) and cord blood (CB) on outcomes in adult acute leukemia (AL) and myelodysplastic syndrome (MDS). Between 2007 and 2015, 231 transplant-eligible patients were registered for a phase 2 study of alternative donor transplantation. After registration, a sufficient time period was given to find appropriate UD. Patients received CB transplantation (CBT) if an appropriate UD was unavailable. In total, 119 patients received CBT (106 AL and 13 MDS) and 91 patients received UD transplantation (UDT) (86 AL and 5 MDS). The median age was 39 years in both groups. The primary objective was overall survival (OS); secondary objectives included cumulative incidences of non-relapse mortality (NRM) and relapse, and disease-free survival. Diagnosis, disease status at transplantation, refined disease risk index, and hematopoietic cell transplant-specific comorbidity index did not differ between UDT and CBT. In multivariate analyses, graft source was not a significant risk factor for all objectives. In adjusted analyses, UDT and CBT showed similar OS, NRM, and relapse in this prospective study. CB can be a comparable alternative stem cell source to UD by achieving a timely transplant.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results